ASH 2023 | Dara-based regimens vs CyBorD in patients with AL amyloidosis & stage IIIb cardiac involvement
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the findings of a matched case-control retrospective study which compared the use of daratumumab (dara)-based regimens and the cyclophosphamide-bortezomib-dexamethasone (CyBorD) regimen in newly diagnosed patients with light chain (AL) amyloidosis and advanced heart involvement (IIIb Mayo cardiac stage). These patients have a poor prognosis and improving outcomes in this advanced stage of disease remains an unmet need. In this study, patients receiving dara-based treatment had a greater overall survival (OS) and progression-free survival (PFS) than those treated with CyBorD, as well as higher rates of hematological response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Pfizer, Jannsen-Cilag
Membership on Board of Directors or advisory committee: Jannsen-Cilag, Siemens
